TEVA [NYSE]
Teva Pharmaceutical Industries Limited
Index- P/E- EPS (ttm)-2.12 Insider Own2.00% Shs Outstand1.11B Perf Week-4.59%
Market Cap9.75B Forward P/E3.38 EPS next Y2.52 Insider Trans-1.82% Shs Float1.10B Perf Month-15.54%
Income-2352.00M PEG- EPS next Q0.56 Inst Own49.60% Short Float / Ratio2.32% / 2.91 Perf Quarter-4.80%
Sales14.93B P/S0.65 EPS this Y-662.70% Inst Trans9.06% Short Interest25.57M Perf Half Y-3.18%
Book/sh7.10 P/B1.20 EPS next Y4.86% ROA-5.20% Target Price10.15 Perf Year8.25%
Cash/sh2.45 P/C3.48 EPS next 5Y3.60% ROE-26.80% 52W Range6.78 - 11.44 Perf YTD-6.47%
Dividend- P/FCF9.36 EPS past 5Y34.30% ROI-5.00% 52W High-25.47% Beta1.22
Dividend %- Quick Ratio0.70 Sales past 5Y-7.80% Gross Margin49.80% 52W Low25.83% ATR0.29
Employees34004 Current Ratio1.10 Sales Q/Q-5.30% Oper. Margin-14.10% RSI (14)28.67 Volatility3.03% 2.48%
OptionableYes Debt/Eq2.69 EPS Q/Q-660.40% Profit Margin-15.80% Rel Volume2.22 Prev Close8.36
ShortableYes LT Debt/Eq2.42 EarningsFeb 08 BMO Payout- Avg Volume8.79M Price8.53
Recom3.10 SMA20-10.48% SMA50-15.79% SMA200-6.00% Volume19,468,374 Change2.03%
Jan-19-23Downgrade Jefferies Buy → Hold $10 → $12
Nov-14-22Downgrade JP Morgan Neutral → Underweight $11 → $10
Nov-04-22Downgrade UBS Neutral → Sell
Oct-21-22Resumed Jefferies Buy $10
Aug-05-22Upgrade BofA Securities Neutral → Buy $10 → $13
Jun-14-22Resumed UBS Neutral $10
May-17-22Upgrade BofA Securities Underperform → Neutral $9
May-04-22Downgrade Piper Sandler Neutral → Underweight $11 → $7
Apr-05-22Upgrade Barclays Equal Weight → Overweight $11 → $13
Mar-25-22Upgrade Bernstein Mkt Perform → Outperform $11
Show Previous Ratings
Mar-17-23 05:54PM
Mar-14-23 10:20PM
Mar-13-23 09:54AM
09:33AM
Mar-09-23 08:00AM
04:00PM Loading…
Mar-07-23 04:00PM
Mar-05-23 11:28AM
Mar-03-23 11:01AM
12:16AM
Mar-01-23 04:11PM
Feb-27-23 03:30AM
03:30AM
Feb-24-23 08:00AM
Feb-23-23 08:00AM
Feb-22-23 07:32AM
04:56PM Loading…
Feb-17-23 04:56PM
Feb-13-23 05:31PM
08:01AM
Feb-09-23 02:29PM
02:24PM
08:29AM
08:00AM
Feb-08-23 04:30PM
04:09PM
12:01PM
11:58AM
08:53AM
07:00AM
05:21AM
Feb-03-23 01:19PM
01:33PM Loading…
Jan-31-23 01:33PM
01:18PM
Jan-27-23 09:40AM
Jan-26-23 09:22AM
Jan-25-23 10:53AM
05:21AM
Jan-24-23 12:26PM
Jan-23-23 04:11PM
11:30AM
Jan-19-23 07:00AM
Jan-14-23 06:15AM
Jan-12-23 04:30PM
Jan-10-23 10:03AM
Jan-09-23 08:34AM
08:22AM
08:19AM
08:00AM
Jan-06-23 07:00AM
04:00AM
Jan-04-23 01:24PM
Jan-03-23 04:30PM
Dec-30-22 06:15AM
Dec-22-22 04:00AM
Dec-21-22 05:21AM
Dec-20-22 08:38AM
Dec-07-22 11:08AM
Dec-05-22 05:21AM
Nov-27-22 12:06PM
10:00AM
Nov-23-22 08:58AM
Nov-22-22 03:01PM
02:53PM
11:30AM
11:25AM
10:05AM
08:30AM
06:00AM
Nov-21-22 10:13AM
07:38AM
07:16AM
07:00AM
01:43AM
Nov-16-22 06:40AM
Nov-14-22 05:02PM
08:01AM
08:00AM
Nov-10-22 08:19AM
Nov-09-22 04:32PM
04:30PM
05:37AM
05:21AM
Nov-07-22 04:30PM
Nov-04-22 06:03PM
10:45AM
Nov-03-22 05:57PM
04:24PM
12:30PM
12:28PM
09:37AM
09:37AM
08:55AM
08:25AM
07:47AM
07:47AM
07:00AM
Nov-02-22 09:25AM
Oct-28-22 06:01PM
Oct-27-22 07:19PM
Oct-25-22 10:00AM
Oct-21-22 06:02PM
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also manufactures and sells active pharmaceutical ingredients, as well as provides contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. In addition, it focuses on the central nervous system (CNS), pain, respiratory, and oncology areas. The company's products portfolio in the CNS field comprises Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; and AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; respiratory therapeutic area includes ProAir RespiClick, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease; and oncology therapeutic field consists of Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dethlefs SvenEVP, North America CommercialMar 07Sale9.4358,066547,440165,381Mar 08 04:03 PM
Daniell RichardExec. VP, European CommercialMar 07Sale9.4354,007509,17369,770Mar 08 04:02 PM
Stark David MatthewExec. VP Chief Legal OfficerMar 07Sale9.4349,475466,4452,974Mar 08 04:05 PM
Drape EricExecutive VP Global OperationsMar 07Sale9.434,69944,302173,262Mar 08 04:04 PM
Dethlefs SvenEVP, North America CommercialMar 06Sale9.9319,355192,213223,447Mar 08 04:03 PM
Daniell RichardExec. VP, European CommercialMar 06Sale9.9318,002178,776123,777Mar 08 04:02 PM
Stark David MatthewExec. VP Chief Legal OfficerMar 06Sale9.9316,491163,77052,449Mar 08 04:05 PM
Drape EricExecutive VP Global OperationsMar 06Sale9.931,56615,552177,961Mar 08 04:04 PM
Stark David MatthewExec. VP Chief Legal OfficerFeb 28Sale9.8963,383626,6422,974Mar 02 07:38 AM
Dethlefs SvenEVP, North America CommercialFeb 28Sale9.8959,655589,785165,381Mar 02 07:33 AM
Daniell RichardExec. VP, European CommercialFeb 28Sale9.8944,252437,50243,182Mar 02 07:33 AM
Drape EricExecutive VP Global OperationsFeb 28Sale9.8933,685333,03087,789Mar 02 07:34 AM
Kalif Eliyahu SharonEVP, Chief Financial OfficerAug 22Sale10.0755,500558,6969,376Aug 24 07:50 AM
Stark David MatthewExec. VP Chief Legal OfficerJul 28Sale9.0458,163525,5902,974Jul 29 07:02 AM
Fridriksdottir HafrunExecutive VP, Global R&DMay 17Sale8.22130,0001,068,0671,387May 19 07:31 AM